Cotrimoxazole plasma levels, dialyzer clearance and total removal by extended dialysis in a patient with acute kidney injury: risk of under-dosing using current dosing recommendations

BMC Clinical Pharmacology

Jan T Kielstein⁴  Gernot Beutel³  Daniel Pietsch²  Johan M Lorenzen⁴  Julius J Schmidt⁴  W Nikolaus Kühn-Velten¹  Christian Clajus⁴ 

[1] Medical Laboratory Bremen, Bremen, Germany;Institute of Clinical Chemistry, Medical School Hannover, Hannover, Germany;Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Medical School Hannover, Hannover, Germany;Department of Nephrology and Hypertension, Medical School Hannover, Hannover, Germany

关键词: Drug monitoring;    Intensive care unit;    Pharmacokinetics;    Antibiotics;   

Others  :  860619
DOI  :  10.1186/2050-6511-14-19

 received in 2012-10-10, accepted in 2013-03-20,  发布年份 2013

【 摘 要 】

Background

Dosing of antibiotics in critically ill patients is challenging. It becomes even more difficult if renal or hepatic impairment ensue. Modern means of renal replacement therapy are capable of removing antibiotics to a higher rate than decades ago, leaving clinicians with a high degree of uncertainty concerning the dose of antibiotics in this patient population. Cotrimoxazole, a combination of trimethoprim (TMP) and sulfamethoxazole (SMX) is frequently used in the treatment of several infections including Pneumocystis jirovecii pneumonia (PCP).

Case presentation

Here we describe a patient with acute kidney injury in which we investigated the TMP and SMX levels during the course of an ICU stay. Cotrimoxazole was administered every six hours i.v. in a dose of TMP/SMX 15/75 mg/kg/day. Extended dialysis was performed with a high-flux dialyzer. Blood samples, as well as pre- and postdialyzer samples and aliquots of the collected spent dialysate were collected.

Observed peak concentrations (Cmax) were 7.51 mg/l for TMP and 80.80 mg/l for SMX. Decline of blood levels during extended dialysis (TMP 64%; SMX 84%) was mainly due to removal by the dialysis procedure, illustrated by the high dialyzer clearances (median of 4 extended dialysis sessions: TMP 94.0 / SMX 51.0 ml/min), as well as by the absolute amount of both substances in the collected spent dialysate (median of 6 extended dialysis sessions: TMP 556 mg / SMX 130 mg). Within the limitation of a case report our data from 4 consecutive extended dialysis sessions suggest that this procedure substantially removes both TMP and SMX.

Conclusions

Dose reduction, which is usually advocated in patients with acute kidney injury under renal replacement therapy, might lead to significant under-dosing. Pharmacokinetic studies for TMP/SMX dosing in this patient population are necessary to allow adequate dosing.

【 授权许可】

   
2013 Clajus et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Cohen SD, Chawla LS, Kimmel PL: Acute kidney injury in patients with human immunodeficiency virus infection. Curr Opin Crit Care 2008, 14(6):647-653.
• [2]Heintz BH, Matzke GR, Dager WE: Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009, 29(5):562-577.
• [3]Curkovic I: Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration. Ann Pharmacother 2010, 44(10):1669-1672.
• [4]Fliser D, Kielstein JT: Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol 2006, 2(1):32-39.
• [5]Kielstein JT, Schiffer M, Hafer C: Back to the future: extended dialysis for treatment of acute kidney injury in the intensive care unit. J Nephrol 2010, 23(5):494-501.
• [6]Czock D: Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol 2006, 1(6):1263-1268.
• [7]Kielstein JT: Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis–a pharmacokinetic study. Nephrol Dial Transplant 2010, 25(5):1537-1541.
• [8]Lorenzen JM: Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis. Clin J Am Soc Nephrol 2012, 7(3):385-390.
• [9]Matzke GR: Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int 2011, 80(11):1122-1137.
• [10]Fliser D, Kielstein JT: A single-pass batch dialysis system: an ideal dialysis method for the patient in intensive care with acute renal failure. Curr Opin Crit Care 2004, 10(6):483-488.
• [11]Gahl G: Kinetic studies on a chemotherapeutic drug combination (sulfamethoxazole and trimethoprim) in chronic kidney insufficiency. Verh Dtsch Ges Inn Med 1971, 77:1017-1019.
• [12]Craig WA, Kunin CM: Trimethoprim-sulfamethoxazole: pharmacodynamic effects of urinary pH and impaired renal function. Studies in humans. Annals of internal medicine 1973, 78(4):491-497.
• [13]Nissenson AR, Wilson C, Holazo A: Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. Am J Nephrol 1987, 7(4):270-274.
• [14]Paap CM, Nahata MC: Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction. DICP: the annals of pharmacotherapy 1989, 23(9):646-654.
• [15]Wharton JM: Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 1986, 105(1):37-44.